The Latest Breaking News from Bristol Myers

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

It's a new day at Bristol Myers, according to a company exec. But the drug giant's stock remains under pressure ahead of a patent cliff.

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.

Most of Bristol Myers' "mature" products delivered commanding third-quarter performances, an analyst said Wednesday as BMY stock rose.

Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.